Dealing with these decisions isn’t easy while undergoing cancer treatment. But yes, it’s completely understandable to ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Prostate cancer is a significant health concern for men worldwide, with increasing diagnoses and fatalities projected. Early ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

A genetics research laboratory has reached a significant milestone in its efforts to recruit 1,000 volunteers for a prostate ...

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced the submission of an extension of ...

In reality, most prostate cancers are detected through routine screening, typically with a simple blood test. Experts ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct ...

He identified age as the leading risk factor, noting that cases are rarely seen in men under 40. Genetics and family history ...

OUR resident specialist and NHS GP, Dr Zoe Williams, shares her expert advice. Today, Dr Zoe helps a reader who is concerned ...